Azenta, Inc. (AZTA) Financial Ratio Screen

NASDAQ Healthcare United States USD 917M
FINANCIAL SCREEN PASSED*
Automated financial screen · activity assessed separately
Azenta, Inc. (AZTA) passes all available checks in 2 implemented financial-ratio model(s). Its activity assessment is still in progress; this is not a Shariah verdict. Its debt proxy is 2.5% against the model threshold of 30%. The supplied classification is Healthcare (Medical Instruments & Supplies); mixed activities and revenue segments remain part of the activity assessment.

Track AZTA screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

AZTA financial screening at a glance

FINANCIAL SCREEN PASSED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
2.5%
Pass vs 30%
Cash ratio
16.6%
Pass vs 30%
Receivables + cash
23.9%
Pass vs 30%
Impermissible income
3.2%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: September 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria passedActivity is assessed separately
FTSE/Yasaar-styleFinancial criteria passedActivity is assessed separately
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodSeptember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Instruments & Supplies) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from September 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 2.5%
/ 30%
16.6%
/ 30%
23.9%
/ 30%
3.16%
/ 5%
FINANCIAL SCREEN PASSED*
FTSE 2.5%
/ 33%
16.6%
/ 33%
23.9%
/ 50%
3.16%
/ 5%
FINANCIAL SCREEN PASSED*

Financial Highlights

P/E Ratio
34.3
Forward: 18.8
EPS
$0.58
P/B Ratio
0.5
EV/EBITDA
15.0
EV: $561M
Revenue
$594M
Growth: 0.8%
Beta
1.4
High volatility
Current Ratio
2.9

Profitability

Gross Margin 44.6%
Operating Margin -4.1%
Net Margin -10.1%
Return on Equity (ROE) 1.5%
Return on Assets (ROA) -0.6%

Cash Flow & Balance Sheet

Operating Cash Flow$72M
Free Cash Flow$38M
Total Debt$51M
Debt-to-Equity3.2
Current Ratio2.9
Total Assets$2.1B

Price & Trading

Last Close$21.31
50-Day MA$28.93
200-Day MA$31.25
Avg Volume813K
Beta1.4
52-Week Range
$19.87
$41.73

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period September 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About Azenta, Inc. (AZTA)

CEO
Mr. John P. Marotta
Employees
3,000
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NASDAQ
Market Cap (listing currency)
USD 917M
Currency
USD

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is Azenta, Inc. (AZTA) halal to invest in?

The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is Azenta, Inc.'s debt ratio?

Azenta, Inc.'s debt ratio is 2.5% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are Azenta, Inc.'s key financial metrics?

Azenta, Inc. has a market capitalization of USD 917M in its listing currency, trailing P/E ratio of 34.3, and revenue of $594M. The company maintains a gross margin of 44.6% and a net margin of -10.1%. Return on equity stands at 1.5%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: September 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.